Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

CML

This page shows the latest CML news and features for those working in and with pharma, biotech and healthcare.

Pfizer gets first FDA nod for hedgehog inhibitor in AML

Pfizer gets first FDA nod for hedgehog inhibitor in AML

indications such as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours.

Latest news

  • Inside the patient-centricity bubble Inside the patient-centricity bubble

    There has been some egregious behaviour in the industry in terms of drug pricing,” he said referring to the net price of CML drugs, which have tripled over the course of

  • Pfizer’s leukaemia drug Mylotarg backed for use in EU Pfizer’s leukaemia drug Mylotarg backed for use in EU

    Kineret (anakinra) in rare inflammatory condition Still’s disease; and Pfizer’s Bosulif (bosutinib) as a treatment for newly-diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia (CML).

  • FDA’s year-end approvals take annual tally to 46 FDA’s year-end approvals take annual tally to 46

    Meanwhile, Novartis got the go-ahead for new labelling for its chronic myeloid leukaemia (CML drug Tasigna (nilotinib. ... It has become the first and only BCR-ABL tyrosine kinase inhibitor (TKI) to include data about attempting treatment discontinuation

  • Novartis' orphan drug Tasigna wins EU expanded indication Novartis' orphan drug Tasigna wins EU expanded indication

    The European Commission approved the drug as a first-line treatment for paediatric patients with newly diagnosed Philadelphia chromosome-positive CML in the chronic phase (Ph+ CML-CP). ... In the studies, patients - aged two-18 years - with newly

  • Takeda's gamble on Ariad pays off with Alunbrig approval Takeda's gamble on Ariad pays off with Alunbrig approval

    Iclusig - approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) - has been a slow-grower, largely because of safety concerns and while it has started to gain traction it

More from news
Approximately 4 fully matching, plus 48 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase

  • Deal Watch May 2016 Deal Watch May 2016

    In addition Incyte was granted an exclusive licence to Inclusig [the only approved BCR-ABL inhibitor with activity against the T315I mutation approved in Europe for chronic myeloid leukaemia (CML) and

  • Seismic shifts: Hepatitis C and payers Seismic shifts: Hepatitis C and payers

    Analogues such as Glivec (imatanib) which transformed outcomes in CML need to be utilised to demonstrate that tough investment decisions by payers do pay off.

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph ALL (JP NDA). ... JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia).

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    treatment. “CML drugs represent real breakthroughs in treatments of patients who would otherwise be very difficult to treat,” he says. ... We hope that Iclusig will be the gift that keeps on giving both in CML and in other indications,” says

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Helen Parfitt joins Research Partnership Helen Parfitt joins Research Partnership

    She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Quick links

Infographics

Multimedia